GT200000161A - Compuestos para el tratamiento de la isquemia. - Google Patents
Compuestos para el tratamiento de la isquemia.Info
- Publication number
- GT200000161A GT200000161A GT200000161A GT200000161A GT200000161A GT 200000161 A GT200000161 A GT 200000161A GT 200000161 A GT200000161 A GT 200000161A GT 200000161 A GT200000161 A GT 200000161A GT 200000161 A GT200000161 A GT 200000161A
- Authority
- GT
- Guatemala
- Prior art keywords
- compounds
- agonists
- profarmacos
- discussion
- ischemia
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 208000028867 ischemia Diseases 0.000 title 1
- 239000000556 agonist Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- -1 OXY, METHYLENE Chemical group 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Genetics & Genomics (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Saccharide Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
ESTA INVENCION SE REFIERE A COMPUESTOS DE LA FORMULA ADJUNTA, PROFARMACOS DE LOS MISMOS Y SALES FARMACEUTICAMENTE ACEPTABLES DE DICHOS COMPUESTOS Y DE DICHOS PROFARMACOS, EN LA QUE X = OXI, METILENO O TIO; Y = CH O N; Z = ES H, ALQUILO, TRIFLUOROMETILO O HALO; LAS DEMAS LETRAS REPRESENTAN UNA GRAN VARIEDAD DE SUSTITUYENTES QUE INDIVIDUAL O CONJUNTAMENTE FORMAN PARTE DE LAS CARACTERISTICAS DE ESTE INGREDIENTE ACTIVO Y DEBERAN COTEJARSE EN EL DOCUMENTO ORIGINAL, LOS COMPUESTOS SON AGONISTAS DE A3 UTILES PARA LA REDUCCION DE LESIONES DE TEJIDOS PRODUCIDAS POR ISQUEMIA O HIPOXIA DE LOS TEJIDOS. EL INVENTO REIVINDICA ADEMAS DEL PROCEDIMIENTO DE SINTESIS DE LOS DIFERENTES COMPUESTOS, LOS PROCEDIMIENTOS PARA USAR TALES AGONISTAS, Y COMPOSICIONES FARMACEUTICAS QUE CONTIENEN TALES AGONISTAS DE A3.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15682899P | 1999-09-30 | 1999-09-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT200000161A true GT200000161A (es) | 2002-03-22 |
Family
ID=22561263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT200000161A GT200000161A (es) | 1999-09-30 | 2000-09-28 | Compuestos para el tratamiento de la isquemia. |
Country Status (41)
| Country | Link |
|---|---|
| EP (1) | EP1216257B1 (es) |
| JP (1) | JP2003510331A (es) |
| KR (1) | KR100481605B1 (es) |
| CN (1) | CN1374967A (es) |
| AP (1) | AP2002002458A0 (es) |
| AR (1) | AR029887A1 (es) |
| AT (1) | ATE312117T1 (es) |
| AU (1) | AU778185B2 (es) |
| BG (1) | BG106636A (es) |
| BR (1) | BR0014384A (es) |
| CA (1) | CA2386079A1 (es) |
| CO (1) | CO5180581A1 (es) |
| CR (1) | CR6592A (es) |
| CZ (1) | CZ20021020A3 (es) |
| DE (1) | DE60024649D1 (es) |
| EA (1) | EA005422B1 (es) |
| EC (1) | ECSP003682A (es) |
| EE (1) | EE200200172A (es) |
| GE (1) | GEP20043241B (es) |
| GT (1) | GT200000161A (es) |
| HK (1) | HK1049011A1 (es) |
| HR (1) | HRP20020253A2 (es) |
| HU (1) | HUP0202807A3 (es) |
| IL (1) | IL148222A0 (es) |
| IS (1) | IS6286A (es) |
| MA (1) | MA26822A1 (es) |
| MX (1) | MXPA02003308A (es) |
| MY (1) | MY133996A (es) |
| NO (1) | NO20021474L (es) |
| NZ (1) | NZ517177A (es) |
| OA (1) | OA12021A (es) |
| PA (1) | PA8503301A1 (es) |
| PE (1) | PE20010696A1 (es) |
| PL (1) | PL357371A1 (es) |
| SK (1) | SK4182002A3 (es) |
| TN (1) | TNSN00191A1 (es) |
| TR (1) | TR200200843T2 (es) |
| UA (1) | UA73525C2 (es) |
| WO (1) | WO2001023399A1 (es) |
| YU (1) | YU23102A (es) |
| ZA (1) | ZA200202461B (es) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6803457B1 (en) | 1999-09-30 | 2004-10-12 | Pfizer, Inc. | Compounds for the treatment of ischemia |
| EP1241176A1 (en) * | 2001-03-16 | 2002-09-18 | Pfizer Products Inc. | Purine derivatives for the treatment of ischemia |
| HUP0401853A2 (hu) * | 2001-11-02 | 2004-12-28 | Aventis Pharmaceuticals Inc. | Gyógyászati készítmény, ami egy adenozin A1/A2 agonistát és nátrium-hidrogén csere inhibitort tartalmaz |
| US7414036B2 (en) | 2002-01-25 | 2008-08-19 | Muscagen Limited | Compounds useful as A3 adenosine receptor agonists |
| AU2003235466C1 (en) * | 2002-04-18 | 2008-03-20 | Gilead Palo Alto, Inc. | Method for treating arrhythmias |
| AR044519A1 (es) | 2003-05-02 | 2005-09-14 | Novartis Ag | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina |
| CA2543913A1 (en) * | 2003-11-10 | 2005-05-26 | Schering Aktiengesellschaft | Benzylether amine compounds useful as ccr-5 antagonists |
| GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| KR20070085093A (ko) | 2004-03-24 | 2007-08-27 | 파스젠, 엘엘씨. | Ａｍｐ-활성화 단백질 키나아제의 약리학적 저해에 의한신규한 신경 보호 방법 |
| NZ551077A (en) | 2004-05-07 | 2009-05-31 | Janssen Pharmaceutica Nv | Pyrrolidin-2-one and piperidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
| GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
| JP4642847B2 (ja) * | 2004-07-28 | 2011-03-02 | キャン−ファイト・バイオファーマ・リミテッド | シェーグレン症候群を含むドライアイ疾患治療用アデノシンａ３レセプターアゴニスト |
| CA2576255A1 (en) * | 2004-08-09 | 2006-02-16 | Universite Catholique De Louvain | Use of agonists and antagonists of beta-adrenoceptors for treating arterial diseases |
| JP5208505B2 (ja) * | 2004-08-30 | 2013-06-12 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | １１−ベータヒドロキシステロイドデヒドロゲナーゼ阻害剤としてのｎ−２アダマンタニル−２−フェノキシ−アセトアミド誘導体 |
| WO2006024628A1 (en) | 2004-08-30 | 2006-03-09 | Janssen Pharmaceutica N.V. | Tricyclic lactam derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
| DE602005017159D1 (de) | 2004-08-30 | 2009-11-26 | Janssen Pharmaceutica Nv | Oxysteroid-dehydrogenase-inhibitoren |
| GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
| GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| MY144906A (en) | 2005-10-21 | 2011-11-30 | Novartis Ag | Human antibodies against il13 and therapeutic uses |
| GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
| MX2009003185A (es) | 2006-09-29 | 2009-04-03 | Novartis Ag | Pirazolopirimidinas como inhibidores de lipido cinasa pi3k. |
| AU2007315234A1 (en) | 2006-10-30 | 2008-05-08 | Novartis Ag | Heterocyclic compounds as antiinflammatory agents |
| CN101910153B (zh) | 2008-01-11 | 2014-01-22 | 诺华股份有限公司 | 作为激酶抑制剂的嘧啶类 |
| PT2391366E (pt) | 2009-01-29 | 2013-02-05 | Novartis Ag | Benzimidazoles substituídos para o tratamento de astrocitomas |
| EP2456419B1 (en) | 2009-07-21 | 2016-11-23 | Oradin Pharmaceutical Ltd. | A3 adenosine receptor ligands for modulation of pigmentation |
| US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
| BR112012003262A8 (pt) | 2009-08-12 | 2016-05-17 | Novartis Ag | compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação |
| PE20121148A1 (es) | 2009-08-17 | 2012-09-07 | Intellikine Llc | Compuestos heterociclicos y usos de los mismos |
| BR112012008061A2 (pt) | 2009-08-20 | 2016-03-01 | Novartis Ag | compostos de oxima heterocíclica |
| UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| EP2673277A1 (en) | 2011-02-10 | 2013-12-18 | Novartis AG | [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase |
| JP5808826B2 (ja) | 2011-02-23 | 2015-11-10 | インテリカイン， エルエルシー | 複素環化合物およびその使用 |
| BR112013021638A2 (pt) | 2011-02-25 | 2016-08-02 | Irm Llc | "compostos inibidores de trk, seu uso e composições que os compreendem" |
| EP2755976B1 (en) | 2011-09-15 | 2018-07-18 | Novartis AG | 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors |
| US20130209543A1 (en) | 2011-11-23 | 2013-08-15 | Intellikine Llc | Enhanced treatment regimens using mtor inhibitors |
| JP2015512425A (ja) | 2012-04-03 | 2015-04-27 | ノバルティス アーゲー | チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用 |
| BR112014027983B1 (pt) | 2012-05-08 | 2022-05-24 | Aeromics, Inc | Uso de inibidores de aquaporina seletivos |
| RU2559776C2 (ru) * | 2012-08-20 | 2015-08-10 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" | Фармацевтические композиции для лечения цереброваскулярных расстройств и способы их изготовления |
| WO2014151147A1 (en) | 2013-03-15 | 2014-09-25 | Intellikine, Llc | Combination of kinase inhibitors and uses thereof |
| RU2691951C2 (ru) | 2013-11-06 | 2019-06-19 | Аэромикс, Инк. | Новые составы |
| WO2015084804A1 (en) | 2013-12-03 | 2015-06-11 | Novartis Ag | Combination of mdm2 inhibitor and braf inhibitor and their use |
| RU2611339C2 (ru) * | 2014-02-17 | 2017-02-21 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" | Фармацевтические композиции с пролонгированным высвобождением для лечения цереброваскулярных расстройств |
| WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
| AU2015294889B2 (en) | 2014-07-31 | 2018-03-15 | Novartis Ag | Combination therapy |
| RU2582961C1 (ru) * | 2015-03-04 | 2016-04-27 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" | Фармацевтические композиции в жидких лекарственных формах для лечения цереброваскулярных расстройств и способы их изготовления |
| US12324807B2 (en) | 2018-06-01 | 2025-06-10 | Cornell University | Combination therapy for PI3K-associated disease or disorder |
| RU2712150C1 (ru) * | 2019-08-22 | 2020-01-24 | Общество с ограниченной ответственностью "ЦЕНТР ТРАНСФЕРА БИОТЕХНОЛОГИЙ ОКА-Биотех" | ПРИМЕНЕНИЕ ТЕТРААЦЕТИЛИРОВАННОГО 5-АМИНО-4-КАРБАМОИЛИМИДАЗОЛИЛ-1-β-D-РИБОФУРАНОЗИДА В КАЧЕСТВЕ ИНГИБИТОРА ПРОТЕИНКИНАЗЫ Cδ |
| TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK62692D0 (es) * | 1992-05-14 | 1992-05-14 | Novo Nordisk As | |
| TW336938B (en) * | 1992-05-21 | 1998-07-21 | Pfizer | Calcium channel blocking polypeptides from filistata hibernalis |
| US5773423A (en) * | 1993-07-13 | 1998-06-30 | The United States Of America As Represented By The Department Of Health And Human Services | A3 adenosine receptor agonists |
-
2000
- 2000-09-05 CO CO00066880A patent/CO5180581A1/es not_active Application Discontinuation
- 2000-09-22 EE EEP200200172A patent/EE200200172A/xx unknown
- 2000-09-22 SK SK418-2002A patent/SK4182002A3/sk unknown
- 2000-09-22 YU YU23102A patent/YU23102A/sh unknown
- 2000-09-22 CN CN00813154A patent/CN1374967A/zh active Pending
- 2000-09-22 PL PL00357371A patent/PL357371A1/xx not_active Application Discontinuation
- 2000-09-22 JP JP2001526549A patent/JP2003510331A/ja active Pending
- 2000-09-22 AP APAP/P/2002/002458A patent/AP2002002458A0/en unknown
- 2000-09-22 HR HR20020253A patent/HRP20020253A2/xx not_active Application Discontinuation
- 2000-09-22 CA CA002386079A patent/CA2386079A1/en not_active Abandoned
- 2000-09-22 EP EP00958949A patent/EP1216257B1/en not_active Expired - Lifetime
- 2000-09-22 HU HU0202807A patent/HUP0202807A3/hu unknown
- 2000-09-22 NZ NZ517177A patent/NZ517177A/en unknown
- 2000-09-22 CZ CZ20021020A patent/CZ20021020A3/cs unknown
- 2000-09-22 AT AT00958949T patent/ATE312117T1/de not_active IP Right Cessation
- 2000-09-22 UA UA2002032515A patent/UA73525C2/uk unknown
- 2000-09-22 DE DE60024649T patent/DE60024649D1/de not_active Expired - Lifetime
- 2000-09-22 AU AU70352/00A patent/AU778185B2/en not_active Ceased
- 2000-09-22 WO PCT/IB2000/001353 patent/WO2001023399A1/en not_active Ceased
- 2000-09-22 GE GEAP20006392A patent/GEP20043241B/en unknown
- 2000-09-22 MX MXPA02003308A patent/MXPA02003308A/es unknown
- 2000-09-22 BR BR0014384-7A patent/BR0014384A/pt not_active IP Right Cessation
- 2000-09-22 EA EA200200316A patent/EA005422B1/ru not_active IP Right Cessation
- 2000-09-22 TR TR2002/00843T patent/TR200200843T2/xx unknown
- 2000-09-22 OA OA1200200072A patent/OA12021A/en unknown
- 2000-09-22 HK HK03101216.3A patent/HK1049011A1/zh unknown
- 2000-09-22 KR KR10-2002-7004177A patent/KR100481605B1/ko not_active Expired - Fee Related
- 2000-09-25 PA PA20008503301A patent/PA8503301A1/es unknown
- 2000-09-27 PE PE2000001021A patent/PE20010696A1/es not_active Application Discontinuation
- 2000-09-28 MY MYPI20004553 patent/MY133996A/en unknown
- 2000-09-28 EC EC2000003682A patent/ECSP003682A/es unknown
- 2000-09-28 GT GT200000161A patent/GT200000161A/es unknown
- 2000-09-28 AR ARP000105125A patent/AR029887A1/es unknown
- 2000-09-29 TN TNTNSN00191A patent/TNSN00191A1/fr unknown
- 2000-09-29 IL IL14822200A patent/IL148222A0/xx unknown
-
2002
- 2002-02-18 CR CR6592A patent/CR6592A/es not_active Application Discontinuation
- 2002-02-26 IS IS6286A patent/IS6286A/is unknown
- 2002-03-15 MA MA26557A patent/MA26822A1/fr unknown
- 2002-03-25 NO NO20021474A patent/NO20021474L/no unknown
- 2002-03-27 ZA ZA200202461A patent/ZA200202461B/xx unknown
- 2002-04-23 BG BG106636A patent/BG106636A/bg unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GT200000161A (es) | Compuestos para el tratamiento de la isquemia. | |
| AR029634A1 (es) | Compuestos derivados heterociclicos utiles como agentes anticancerosos, composicion farmaceutica y procedimiento de tratamiento | |
| AR126701A1 (es) | Derivados de n-ciclopropilpirido[4,3-d]pirimidin-4-amina y usos de los mismos | |
| UY26872A1 (es) | Derivados de la 4- fenil piridina | |
| PA8591701A1 (es) | Derivados de pirrolopirimidina | |
| PA8442001A1 (es) | Derivados de pirimidina biciclica condensada | |
| GT200000005A (es) | Derivados biciclicos sustituidos utiles como agentes contra el cancer. | |
| CO4810375A1 (es) | Derivados de 9-amino-3-ceto eritromicina | |
| AR048039A1 (es) | Profarmacos de piperazina y agentes antivirales de piperidina sustituidos | |
| PA8489501A1 (es) | Antibioticos cetolidos | |
| PA8507601A1 (es) | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos | |
| UY27350A1 (es) | Azaindoles | |
| PA8580301A1 (es) | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos | |
| PA8547701A1 (es) | Nucleosidos 4 substituidos. | |
| CR7069A (es) | Derivados de pirazol para el tratamiento de vih | |
| SV2002000504A (es) | Derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal ref.pc10760/20205/bb | |
| PA8593101A1 (es) | Composiciones para el tratamiento de crecimiento celular anormal | |
| ECSP066643A (es) | PIRIDO [2,3-d] PIRIMIDINA-2,4-DIAMINAS COMO INHIBIDORES DE PDE 2 | |
| AR040925A1 (es) | Compuestos de pirazol utiles como inhibidores de proteinquinasa | |
| AR028810A1 (es) | Derivados de arilpiperazinil-ciclohexil indol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos para el tratamiento de la depresion | |
| CO5271715A1 (es) | 7-aza-indolin-2-onas sustituidas en 4 y su uso como inhibidores de proteiuna quinasa | |
| PA8559501A1 (es) | Formulaciones farmaceuticas de 5,7,14-triazatetraciclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaeno | |
| PA8451801A1 (es) | Derivados de la 9-oxima eritromicina | |
| ES2187518T3 (es) | 3-(aminoalquilamino)-1-2-benzisoxazoles sustituidos y compuestos relacionados. | |
| MX2024012541A (es) | Compuestos heterociclicos como moduladores del linfoma de celulas b 6 (bcl6) como degradadores dirigidos a ligando |